Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8872810 | 0.88 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6555223 | 0.88 | TACR1 (0.80) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6555215 | 0.88 | TACR1 (0.80) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6554720 | 0.88 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6555227 | 0.88 | TACR1 (0.80) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8872819 | 0.88 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6554698 | 0.88 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6554707 | 0.88 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6554709 | 0.88 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6557108 | 0.88 | TACR1 (0.77) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162766-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1209157-A1 | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds | PFIZER INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6369074-B1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. | 2002-04-09 | — | — | US | disclosed |
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | HOWARD HARRY R (US) | 2001-09-20 | — | — | US | disclosed |
| EP-0675886-B1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5854262-A | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5703065-A | Heteroarylamino and heteroarylsulfonamido substituted 3-benyzlaminomethyl piperidines and related compounds | PFIZER INC. (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0806423-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists | PFIZER INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0675886-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1995007908-A1 | HETEROARYLAMINO AND HETEROARYLSULFONAMIDO SUBSTITUTED 3-BENZYLAMINOMETHYL PIPERIDINES AND RELATED COMPOUNDS | PFIZER INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1994013663-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | NPY1R, OPRK1, OPRL1 | TACR1 5/4885CYP2D6 702/4885KCNH2 652/4885 |
| US-20030162766-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | NPY1R, OPRK1, TACR1 | TACR1 3/4885CYP2D6 879/4885KCNH2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.